![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing aims to fund the company’s lead product, MAR001, a monoclonal antibody targets ANGPTL4. Currently, it is being evaluated in early-stage trials for the treatment of hypertriglyceridemia.
Lead Product(s): MAR001
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MAR001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sofinnova Investments
Deal Size: $190.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 18, 2024